adUnits.push({
code: ‘Rpp_mundo_actualidad_Nota_Interna1’,
mediaTypes: {
banner: {
sizes: (navigator.userAgent.match(/iPhone|android|iPod/i)) ? [[300, 250], [320, 460], [320, 480], [320, 50], [300, 100], [320, 100]] : [[300, 250], [320, 460], [320, 480], [320, 50], [300, 100], [320, 100], [635, 90]]
}
},
bids: [{
bidder: ‘appnexus’,
params: {
placementId: ‘14149971’
}
},{
bidder: ‘rubicon’,
params: {
accountId: ‘19264’,
siteId: ‘314342’,
zoneId: ‘1604128’
}
},{
bidder: ‘amx’,
params: {
tagId: ‘MTUybWVkaWEuY29t’
}
},{
bidder: ‘oftmedia’,
params: {
placementId: navigator.userAgent.match(/iPhone|android|iPod/i) ? ‘22617692’: ‘22617693’
}
}]
});
One injection of new antiviral treatment against COVID-19, in phase clinical trials, halved the risk of hospitalization if infected, according to a study published on Wednesday.
He said that even when COVID-19 is no longer on the front pages, developing new treatment options remains critical, especially against new options. AFP Geoffrey Glennprofessor of immunology at Stanford University and co-author of a study published in the journal NEZHM.
About 500 people still die every day from this disease in USA.
The treatment uses interferons, key proteins in the response immune. They are released in the presence of a virus and attach to receptors on certain cells, triggering an “innate antiviral defense mechanism” (other than antibodies), Glenn explained.
There are several classes of interferons, including the so-called lambdas. Their specialty is that they especially adhere to lung cells, exactly where COVID-19 wreaks havoc.
Positive results
He care It consists of an injection of a synthetic version of lambda interferons within seven days of the onset of the first symptoms of COVID-19.
This has been tested in clinical trials on over 1900 infected adults from COVID-19, between June 2021 and February 2022 in Brazil and Canada. At the same time, 85% of patients have already been vaccinated.
Among the 931 people who received treatment, 25 were hospitalized, compared with 57 of 1,018 patients who received placebo, or a 51% decrease, according to the study. The results are even better when isolating unvaccinated patients.
“That’s impressive,” says Glenn, also the founder of the biopharmaceutical company Eiger, which developed the treatment and is still a shareholder.
This is a one time treatment. injection It offers a practical advantage over Pfizer’s antiviral drug Paxlovid, which requires dozens of pills to be taken over five days, he says. (AFP)
Source: RPP
I’m a passionate and motivated journalist with a focus on world news. My experience spans across various media outlets, including Buna Times where I serve as an author. Over the years, I have become well-versed in researching and reporting on global topics, ranging from international politics to current events.